Printer Friendly

JESS L. BELSER RESIGNS FROM IMMULOGIC BOARD OF DIRECTORS

       JESS L. BELSER RESIGNS FROM IMMULOGIC BOARD OF DIRECTORS
    CAMBRIDGE, Mass., Nov. 15 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) said today that Jess L. Belser has resigned from the company's board of directors.  Belser is senior managing director of Rothschild North America.  "Jess Belser has played an important role in guiding the development of ImmuLogic, from its inception in 1987 through its successful initial public offering in May 1991," said Richard Bagley, president and CEO of ImmuLogic.
    Belser stated that his resignation is in keeping with Rothschild's policy to withdraw from board positions after companies become well established as publicly traded firms.  ImmuLogic Pharmaceutical Corporation is developing a family of ALLERVAX(tm) products to treat allergic diseases.  The company is also collaborating with Merck & Co. to develop treatments for Type I diabetes and rheumatoid arthritis.
    -0-                        11/15/91
    /CONTACT: Janet C. Bush, vice president, finance and administration,  ImmuLogic Pharmaceutical Corportion, 617-494-0060/
    (IMUL) CO:  ImmuLogic Pharmaceutical Corporation ST:  Massachusetts IN:  MTC SU:  PER KM-DD -- NE012 -- 1585 11/15/91 13:23 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:172
Previous Article:BANKATLANTIC FINANCIAL REPORTS THIRD QUARTER RESULTS
Next Article:NINTENDO ADDS HIGH-TECH TOUCH TO WHATCOM MUSEUM; VIDEO GAMES HIGHLIGHTED IN HISTORY OF GAMES EXHIBIT
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
IMMULOGIC STUDIES OPEN WAY TO NEW TREATMENTS FOR ALLERGIC DISEASES
IMMULOGIC VICE PRESIDENT JANET C. BUSH WILL RESIGN AUG. 31, 1992
ImmuLogic Files Investigational New Drug Application with the FDA for Multiple Sclerosis Therapeutic
ImmuLogic Reports First Quarter 1997 Financial Results
Dyax Corp. Names Shirish Hirani Vice President of Program Management, Research Division
Immulogic Announces Sales of Its Drugs of Addiction Vaccines Programs to Cantab Pharmaceuticals.
ImmuLogic to Sell Shares of Cantab Pharmaceuticals Plc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters